<DOC>
	<DOCNO>NCT00245271</DOCNO>
	<brief_summary>OMS103HP develop improvement knee function follow ACL reconstruction . Secondary benefit evaluate include reduce postoperative pain , improvement knee motion earlier return work .</brief_summary>
	<brief_title>Safety OMS103HP Patients Undergoing Anterior Cruciate Ligament ( ACL ) Reconstruction</brief_title>
	<detailed_description>The anterior cruciate ligament ( ACL ) important stabilizer knee . Orthopedic surgeon replace torn ligament ACL reconstruction surgery . Surgical trauma initiate acute inflammatory response , include swell pain , lead restrict joint motion loss function . Because dynamic nature , complexity redundancy chemical mediator inflammation pain pathway , currently available single drug sufficiently broad spectrum activity effectively inhibit inflammatory process . OMS103 provide multicomponent approach control inflammation induce arthroscopic surgery . It deliver three active ingredient , distinct pharmacological activity , directly site surgical procedure preemptively block inflammatory cascade induce surgical trauma .</detailed_description>
	<criteria>17 65 year age In good general health Undergoing arthroscopic ACL reconstruction ACL tear Allergies individual ingredient OMS103HP Has open physes distal femur proximal tibia Undergoing bilateral knee surgery Subject consider Investigator unsuitable candidate</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Knee</keyword>
	<keyword>Musculoskeletal System</keyword>
	<keyword>Ligament</keyword>
	<keyword>ACL reconstruction</keyword>
</DOC>